FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma

On December 4, the FDA approved lisocabtagene maraleucel for adults with relapsed or refractory marginal zone lymphoma who have received at least 2 prior lines of systemic therapy.

For more information, read the FDA announcement and the Bristol Myers Squibb press release.

Posted on 12/5/2025